Trium Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Simulations Plus
SLP
|
+$12.4M |
| 2 |
Genco Shipping & Trading
GNK
|
+$4.55M |
| 3 |
Snowflake
SNOW
|
+$2.69M |
| 4 |
BioLife Solutions
BLFS
|
+$2.58M |
| 5 |
Middleby
MIDD
|
+$1.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Esperion Therapeutics
ESPR
|
+$35.3M |
| 2 |
AT&T
T
|
+$22.5M |
| 3 |
Sapiens International
SPNS
|
+$7.56M |
| 4 |
Alumis Inc
ALMS
|
+$3.92M |
| 5 |
Wabtec
WAB
|
+$2.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 40.47% |
| 2 | Healthcare | 21.82% |
| 3 | Industrials | 15.62% |
| 4 | Technology | 6.33% |
| 5 | Real Estate | 5.88% |
No holdings matched the selected filter criteria.
Similar funds
Trium Capital's Q3 2026 Portfolio in Review
As of Q3 2026, Trium Capital held 73 positions worth $79.4M, down 51% from $163M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Trium Capital withdrew a net $71.8M in Q3 2026, closing 20 positions and reducing 32 holdings. Its most notable exit was Esperion Therapeutics, an estimated $35.3M position sold in full.
By sector, the portfolio is most concentrated in Communication Services at 40% of assets, up from 36% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Trium Capital opened a new position in Simulations Plus worth $12.4M.
- Trium Capital's largest Q3 2026 buy was Simulations Plus: 673,172 shares worth $12.4M.
- Trium Capital added most to Shoals Technologies Group in Q3 2026, an estimated $72.2K increase.
- Trium Capital's biggest Q3 2026 reduction was AT&T, cutting an estimated $22.5M.
- Trium Capital fully exited Esperion Therapeutics in Q3 2026, selling an estimated $35.3M.
- Trium Capital's ten largest holdings make up 82% of its $79.4M portfolio in Q3 2026.
- Trium Capital opened 20 new positions and closed 20 in Q3 2026.
- Trium Capital's portfolio value fell 51% quarter-over-quarter to $79.4M.
Based on Trium Capital's 13F filing for Q3 2026, filed 16 Oct 2026.